HCS-Splice: A High-Content Screening Method to Advance the Discovery of RNA Splicing-Modulating Therapeutics.

FTDP-17 MAPT alternative splicing drug discovery exon-skipping high content screening nucleic acids therapeutics siRNA two-colour (GFP/RFP) fluorescent reporter

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
28 07 2023
Historique:
received: 25 06 2023
revised: 10 07 2023
accepted: 13 07 2023
medline: 14 8 2023
pubmed: 11 8 2023
entrez: 11 8 2023
Statut: epublish

Résumé

Nucleic acid therapeutics have demonstrated an impressive acceleration in recent years. They work through multiple mechanisms of action, including the downregulation of gene expression and the modulation of RNA splicing. While several drugs based on the former mechanism have been approved, few target the latter, despite the promise of RNA splicing modulation. To improve our ability to discover novel RNA splicing-modulating therapies, we developed HCS-Splice, a robust cell-based High-Content Screening (HCS) assay. By implementing the use of a two-colour (GFP/RFP) fluorescent splicing reporter plasmid, we developed a versatile, effective, rapid, and robust high-throughput strategy for the identification of potent splicing-modulating molecules. The HCS-Splice strategy can also be used to functionally confirm splicing mutations in human genetic disorders or to screen drug candidates. As a proof-of-concept, we introduced a dementia-related splice-switching mutation in the Microtubule-Associated Protein Tau (

Identifiants

pubmed: 37566038
pii: cells12151959
doi: 10.3390/cells12151959
pmc: PMC10417277
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nucleic Acid Ther. 2022 Aug;32(4):333-349
pubmed: 35166581
Mol Biol Evol. 2014 Jun;31(6):1402-13
pubmed: 24682283
Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11218-23
pubmed: 18678901
Front Mol Neurosci. 2015 Mar 19;8:9
pubmed: 25852467
Brain. 2010 Apr;133(Pt 4):957-72
pubmed: 20150322
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8764-9
pubmed: 15939885
Mol Cell Biol. 2000 Jun;20(11):4036-48
pubmed: 10805746
Auton Neurosci. 2002 Nov 29;102(1-2):71-7
pubmed: 12492138
Biochim Biophys Acta. 2000 Jul 26;1502(1):110-21
pubmed: 10899436
Sci Rep. 2021 Dec 14;11(1):23935
pubmed: 34907283
Nucleic Acid Ther. 2014 Feb;24(1):69-86
pubmed: 24506781
Trends Genet. 2019 Jan;35(1):68-87
pubmed: 30466729
J Biomol Screen. 1999;4(2):67-73
pubmed: 10838414
Mol Neurodegener. 2017 Jan 24;12(1):10
pubmed: 28118852
RNA. 2009 Oct;15(10):1896-908
pubmed: 19656867
Nat Genet. 2008 Dec;40(12):1413-5
pubmed: 18978789
BMC Neurosci. 2008 Dec 03;9 Suppl 2:S10
pubmed: 19090983
Methods Mol Biol. 2017;1648:221-233
pubmed: 28766300
Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19 Suppl 1:S29-36
pubmed: 16317255
Lab Invest. 2019 Jul;99(7):912-928
pubmed: 30742061
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5598-603
pubmed: 10318930
RNA. 2006 May;12(5):925-30
pubmed: 16556940
RNA. 2006 Jun;12(6):1129-41
pubmed: 16603716
Nature. 2008 Nov 27;456(7221):470-6
pubmed: 18978772
Trends Genet. 2001 Feb;17(2):100-7
pubmed: 11173120
Nat Rev Neurosci. 2023 Aug;24(8):457-473
pubmed: 37336982
Mol Ther Nucleic Acids. 2016 Oct 25;5(10):e380
pubmed: 27779620
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7737-41
pubmed: 9636220
Biochim Biophys Acta. 2012 Jul;1819(7):673-83
pubmed: 22326677
Biochemistry. 2019 Mar 26;58(12):1565-1578
pubmed: 30793898
Ann Neurol. 1992 Sep;32(3):312-20
pubmed: 1416801
Am J Med Genet. 1997 Jul 25;74(4):380-5
pubmed: 9259373
Nature. 2010 Jan 28;463(7280):457-63
pubmed: 20110989
Mol Cell Biol. 2004 Dec;24(24):10505-14
pubmed: 15572659
Genome Res. 2013 Jun;23(6):998-1007
pubmed: 23636947
Annu Rev Biochem. 2015;84:291-323
pubmed: 25784052
Chromosoma. 2013 Jun;122(3):191-207
pubmed: 23525660
Nat Protoc. 2010 Sep;5(9):1495-517
pubmed: 20725066
Front Neurosci. 2021 May 25;15:643115
pubmed: 34113229
PLoS One. 2018 Apr 10;13(4):e0195771
pubmed: 29634760
Nature. 1998 Jun 18;393(6686):702-5
pubmed: 9641683
Gene Ther. 2001 Oct;8(20):1532-8
pubmed: 11704813
Hum Mutat. 2003 Jun;21(6):577-81
pubmed: 12754702
Nucleic Acids Res. 2006;34(22):e148
pubmed: 17142220
Adv Exp Med Biol. 2007;623:123-47
pubmed: 18380344
Acta Neuropathol. 1999 Jul;98(1):62-77
pubmed: 10412802
Nat Rev Mol Cell Biol. 2009 Nov;10(11):741-54
pubmed: 19773805
J Biol Chem. 2006 Aug 25;281(34):24479-88
pubmed: 16777844
Curr Opin Genet Dev. 2011 Aug;21(4):373-9
pubmed: 21530232

Auteurs

Giuseppina Covello (G)

RNA Biology and Biotechnology Laboratory, Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.

Kavitha Siva (K)

RNA Biology and Biotechnology Laboratory, Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.

Valentina Adami (V)

High Throughput Screening and Validation Core Facility (HTS), Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.

Michela Alessandra Denti (MA)

RNA Biology and Biotechnology Laboratory, Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH